Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone-Reference-Cited by-同舟云学术

Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone

Published:2017-11-09 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Boeri Luca,Capogrosso Paolo,Ventimiglia Eugenio,Cazzaniga Walter,Pederzoli Filippo^ORCID,Moretti Donatella,Dehò Federico,Montanari Emanuele,Montorsi Francesco,Salonia Andrea

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-15435-0.pdf

Reference30 articles.

1. Gratzke, C. et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67, 1099–109 (2015).

2. Ficarra, V. et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep 15, 463–9 (2014).

3. Nickel, J. C. et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 54, 1379–84 (2008).

4. Nickel, J. C., Roehrborn, C. G., Castro-Santamaria, R., Freedland, S. J. & Moreira, D. M. Chronic prostate inflammation is associated with severity and progression of benign prostatic hyperplasia, lower urinary tract symptoms and risk of acute urinary retention. J Urol 196, 1493–8 (2016).

5. Russo, A. et al. Latest pharmacotherapy options for benign prostatic hyperplasia. Expert Opin Pharmacother 15, 2319–28 (2014).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of combination therapy of Croton membranaceus and finasteride on benign prostatic hyperplasia (BHP) histo-morphology;Phytomedicine Plus;2024-05

2. Immediate effect of alpha-blockers in predicting LUTS improvement in BPH patients;Urologia Journal;2023-08-22

3. Overview of current pharmacotherapeutic options in benign prostatic hyperplasia;Expert Opinion on Pharmacotherapy;2023-07-21

4. Lipid Profile and 5α-Reductase Inhibition Activity of Proprietary Ultrahigh-Pressure Supercritical Carbon Dioxide and Hexane Saw Palmetto Extracts;Uro;2023-01-17

5. The Role of Combination Therapy with α-Blockers and Hexanic Extract of Serenoa repens in the Treatment of LUTS/BPH;Journal of Clinical Medicine;2022-12-02